NOXXON Pharma N.V.: NOXXON Enrolls Last Brain Cancer Patient in Dose Escalation Portion of GLORIA Study and Confirms Phase 1/2 Read-Out in Q1 2022

Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces today

Related Keywords

Paris ,France General ,France ,Arthur Rouill ,Aram Mangasarian ,Ulf Jungnelius ,Pharmanv Euronext ,Merck Keytruda ,Guillaume Van Renterghem ,Linkedin ,Twitter ,Merck Sharp Dohme Corp ,Regulatory News ,Euronext Growth Paris ,Jarl Ulf Jungnelius ,Senior Medical Advisor ,Executive Officer ,Media Relations ,பாரிஸ் ,பிரான்ஸ் ,சென்டர் ,ட்விட்டர் ,ஒழுங்குமுறை செய்தி ,நிர்வாகி அதிகாரி ,மீடியா உறவுகள் ,Noxxon ,Dharma ,Enrolls ,Mast ,Rain ,Dancer ,Patient ,Nose ,Escalation ,Portion ,Gloria ,Study ,Onfirms ,Hase ,Head ,022 ,